NCT00673569View on ClinicalTrials.gov

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

July 31, 2007

Conditions
Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

GENETIC

gene expression analysis

GENETIC

protein expression analysis

OTHER

immunoenzyme technique

OTHER

immunologic technique

OTHER

laboratory biomarker analysis

PROCEDURE

needle biopsy

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00673569 - Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment | Biotech Hunter | Biotech Hunter